The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 3 (February 2008) of the Risk Management Plan (RMP) presented with the first PSUR and any subsequent updates of the RMP agreed by the CHMP.